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by Elsevier B.V. All rights reserved.For many years, liver cell biologists have concentrated almost
exclusively on hepatocytes. It is only in the last two decades that
the identiﬁcation of the cellular and molecular mechanisms of
ﬁbrogenesis has directed the attention of several investigators
to the role played by hepatic myoﬁbroblasts and by the complex
networks involving parenchymal and non-parenchymal cells [1].
Even more recently, many groups investigating hepatic ﬁbrogen-
esis have started to look outside the liver, in order to understand
if signals derived from other systems may affect the hepatic
‘wound healing’ response that leads to tissue ﬁbrosis. Adipose tis-
sue is a clear example of how changes in extrahepatic sites may
inﬂuence the ﬁbrogenic process, as highlighted by clinical studies
that have indicated the detrimental role played by fat accumula-
tion on the development and progression of chronic liver diseases
[2]. As a molecular counterpart, leptin and adiponectin, which are
increased and decreased in obese patients, respectively, play
opposite roles in the modulation of the ﬁbrogenic process [3].
At a different level, the bone marrow has been shown to provide
the liver with ﬁbrogenic cells, or to limit the development of
ﬁbrosis with the contribution of different cell types [4].
Ghrelin, the focus of the paper by Moreno et al. [5], expands
the list of extrahepatic factors, which modulate the ﬁbrogenic
process. Ghrelin is mainly produced by enteroendocrine cells of
the gastric mucosa and secreted in the circulation, to exert hor-
monal action on different tissues [6]. Originally identiﬁed for its
role in the release of growth hormone and as a potent stimulant
of appetite, ghrelin is also implicated in development, gastroin-Journal of Hepatology 20
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secretagogue receptor 1a (GHS-R1a), which belongs to the
seven-transmembrane domain superfamily. Nonetheless, there
are actions of ghrelin that are mediated by a yet unrecognized
receptor.
Moreno et al. [5] have used a panel of experimental
approaches in rodents and humans to provide evidence that
ghrelin has antiﬁbrotic effects in the liver (Fig. 1). In rats sub-
jected to ligation of the common bile duct, a well-established
model of ﬁbrosis, both recombinant ghrelin and a speciﬁc agonist
of GHS-R1a resulted in a signiﬁcant reduction of ﬁbrotic tissue
accumulation. This was associated with modulation of hepatic
gene expression in agreement with the observed antiﬁbrotic
effects. Complementary data were obtained in mice defective in
the ghrelin gene, where the absence of endogenous ghrelin
resulted in more marked ﬁbrosis upon chronic carbon tetrachlo-
ride administration. The cellular and molecular mechanisms of
the anti-ﬁbrogenic action of ghrelin were also investigated in
detail. An important feature of animals treated with ghrelin
was the lower degree of hepatocellular injury, highlighted by
dedicated experiments using an acute toxic model of liver injury.
The ability of ghrelin to counteract tissue damage is in line with
the protective roles reported in other tissues [7,8]. In the liver,
ghrelin affected several components of tissue injury, namely
inﬂammation, apoptosis, and generation of oxidative stress-
related molecules (Fig. 1). These actions, which by themselves
may justify a reduced ﬁbrogenic stimulus, were associated with
direct effects on many, but not all, the proﬁbrogenic features of
activated stellate cells, thus providing another level of modula-
tion of the tissue repair process. Interestingly, while activation
of the GHS-R1a was sufﬁcient to reproduce the effects of ghrelin,
it is possible that other, yet unknown, membrane receptors con-
tributed to the observed effects.
This study is a brilliant example of translational research,
where the role of a putative factor and its mechanisms of action
were studied in cultured cells, animal models, and ﬁnally in
humans. In fact, circulating levels of ghrelin were lower in
patients with advanced ﬁbrosis and a polymorphism of the ghre-
lin gene segregated individuals with faster ﬁbrosis progression
during chronic HCV infection. Thus, these data provide strong
pre-clinical evidence for a possible interventional study evaluat-
ing the role of ghrelin as an antiﬁbrotic agent. The good news is
that this peptide is already being investigated in clinical trials
for several disorders in humans (clinicaltrials.gov, accessed
November 10, 2010), and its safety proﬁle could be less of a
concern compared to other ‘experimental’ anti-ﬁbrogenic11 vol. 55 j 221–223
Fig. 1. Regulatory mechanisms of the hepatic response to injury by ghrelin. Ghrelin is secreted by the stomach and acts at distant sites in a hormonal fashion, but it may
also be produced locally. The work by Moreno et al. [5] (blue arrows) shows that ghrelin exerts several hepatoprotective actions limiting hepatic damage and the resulting
proﬁbrogenic stimuli. In addition ghrelin may interfere with the pathophysiology of liver tissue through actions, demonstrated by other groups (red arrows), directly on
liver cells or on other tissues.
International Hepatologytherapies. Interestingly, treatment with ghrelin has also been
suggested for patients with end-stage liver disease, where anor-
exia and malnutrition are common.
The effects of ghrelin on ﬁbrosis are another piece of the puz-
zle that puts together metabolic regulation and the wound heal-
ing response. In recent years, leptin, a potent regulator of food
intake and lipid partitioning, has emerged as an important stim-
ulus to hepatic ﬁbrogenesis, with actions on hepatic stellate cells
and other non-parenchymal cells [9,10]. The actions of leptin on
the hypothalamus are contrary to those of ghrelin, resulting in
the stimulation of neuronal circuits that reduce appetite, and
the observed anti-ﬁbrogenic effects of ghrelin identify an addi-
tional condition in which these two hormones have opposing
effects. Adiponectin and leptin, which also have opposite actions
in terms of ﬁbrogenesis [3], are mutually regulated in hepatic
stellate cells [11], and it will be interesting to investigate whether
ghrelin or leptin affect their reciprocal expression or that of their
receptors. Along these lines, leptin prevents ectopic fat deposition
through central and peripheral mechanisms, these latter includ-
ing activation of hepatic AMP-activated protein kinase (AMPK)222 Journal of Hepatology 201[3]. In contrast, ghrelin has been found to favor hepatic steatosis
and to inhibit hepatic AMPK activation [12]. AMPK activation by a
given ligand is cell-speciﬁc, and AMPK has been recently
identiﬁed as an anti-ﬁbrogenic pathway in HSC [13]. Thus, the
possibility that at least some of the effects of ghrelin are
mediated through activation of this pathway deserves future
investigation.
Soluble factors targeting the liver from distant sites act as cir-
culating hormones. Nonetheless, components of a wide number
of these systems are also expressed within the liver, suggesting
that at least some of their actions may be mediated by local
ligand generation. Moreno et al. [5] found that the ghrelin gene
is expressed in normal and ﬁbrotic human livers, and that both
hepatocytes and HSC contribute to its expression. Nonetheless,
other cells within the liver may express ghrelin, and additional
work is required to better elucidate the cellular sources of this
factor in the normal and inﬂamed tissue. Hepatic expression of
ghrelin is reminiscent of data previously reported for other ‘sys-
temic’ factors, such as the renin-angiotensin system, and several
adipokines, including leptin and adiponectin [11,14]. Interest-1 vol. 55 j 221–223
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ingly, intrahepatic expression of ghrelin was found to directly
correlate with expression of proﬁbrogenic genes, and patients
with a haplotype of the promoter that is transcriptionally more
active had more severe ﬁbrosis. Although these ﬁndings sound
surprising based on the anti-ﬁbrogenic effects of ghrelin in
animal models, they raise the hypothesis that the liver may be
resistant to the effects of ghrelin, despite its increase in local
expression. Resistance to leptin has been shown in obese patients
and its mechanisms partially unraveled [15], and additional data
on ghrelin are awaited.
The data provided by Moreno et al. [5] advocate the adminis-
tration of recombinant ghrelin or stimulation of its signaling as a
possible treatment strategy for liver ﬁbrosis. However, antago-
nism of ghrelin’s action has been suggested for the therapy of
other conditions, such as obesity and fatty liver. In fact, ghrelin-
deﬁcient mice were less susceptible to obesity, and in conditions
of excess adiposity, reduction of ghrelin-mediated signal may
reduce hyperphagia and lead to weight loss [16,17]. As obesity
and steatosis are well-known risk factors for the progression of
chronic liver diseases, the possibility that chronic ghrelin admin-
istration could favor these conditions must be taken into account.
Conversely, antagonism of ghrelin’s action, proposed for the
treatment of obesity, may favor the progression of ﬁbrosis in a
population with a high prevalence of nonalcoholic liver disease
and in general more susceptible to accelerated ﬁbrogenesis
[18]. Another point that will deserve further clariﬁcation is
related to the observed mitogenic effect of ghrelin on cultured
cancer cells, including hepatocellular carcinoma cells [19]. As a
treatment of ﬁbrosis is expected to encompass a long period of
time, and ﬁbrogenic liver diseases are preneoplastic conditions,
the possibility that ghrelin promotes the appearance or progres-
sion of hepatocellular carcinoma is a critical issue. In spite of
these caveats, it is from well-conducted and methodologically
sound work like the one performed by Moreno et al. that new
approaches for the treatment of ﬁbrosis are likely to be
developed.
A post-translational modiﬁcation of ghrelin results in acyla-
tion of serine-3 with an eight-carbon fatty acid, octanoate.
While des-acyl ghrelin, the peptide devoid of the acyl moiety,
has been long considered a non-functional form of ghrelin,
recent data indicate that it actually participates in the regula-
tion of food intake, gastrointestinal physiology, and metabo-
lism, with actions that are in general opposite to those
elicited by ghrelin [6]. This may have relevance also for hepatic
ﬁbrosis, considering that des-acyl ghrelin represent the most
abundant form secreted in the circulation. Ghrelin O-acyltrans-
ferase (GOAT) is the enzyme which catalyzes acylation of des-
acyl ghrelin to provide ghrelin. Expression of GOAT is limited
to tissues that secrete ghrelin, and the reaction is highly spe-
ciﬁc for this peptide [6]. Thus, future investigations should take
into account the regulation of GOAT, and interference with its
activity is currently being considered to modulate the ghrelin
system. The complexity of the system is further demonstrated
by the existence of two additional products of the ghrelin gene,
des-Gln14-ghrelin, which is created by alternative splicing and
binds GHS-R1a, and obestatin. The pathophysiological role of
obestatin in the regulation of metabolism and other conditions
is being actively investigated.Journal of Hepatology 201Conﬂict of interest
The author declared that he does not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
Acknowledgments
Work in Dr. Marra’s laboratory is supported by grants from the
European Community’s Seventh Framework Programme (FP7/
2007-2013) under grant agreement n HEALTH-F2-2009-
241762 for the project FLIP. Associazione Italiana per la Ricerca
sul Cancro (AIRC), and Istituto Toscano Tumori (ITT).
References
[1] Friedman SL. Mechanisms of hepatic ﬁbrogenesis. Gastroenterology
2008;134:1655–1669.
[2] Diehl AM. Hepatic complications of obesity. Gastroenterol Clin North Am
2010;39:57–68.
[3] Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009;50:
957–969.
[4] Alison MR, Islam S, Lim S. Stem cells in liver regeneration, ﬁbrosis and
cancer: the good, the bad and the ugly. J Pathol 2009;217:282–298.
[5] Moreno M, Chaves JF, Sancho-Bru P, Ramalho F, Ramalho LN, Mansego ML,
et al. Ghrelin attenuates hepatocellular injury and liver ﬁbrogenesis in
rodents and inﬂuences ﬁbrosis progression in humans. Hepatology 2010;51:
974–985.
[6] Chen CY, Asakawa A, Fujimiya M, Lee SD, Inui A. Ghrelin gene products and
the regulation of food intake and gut motility. Pharmacol Rev 2009;61:
430–481.
[7] Jacob A, Shah KG, Wu R, Wang P. Ghrelin as a novel therapy for radiation
combined injury. Mol Med 2010;16:137–143.
[8] Zhou X, Xue C. Ghrelin inhibits the development of acute pancreatitis and
nuclear factor kappaB activation in pancreas and liver. Pancreas 2009;38:
752–757.
[9] Marra F. Leptin and liver tissue repair: do rodent models provide the
answers? J Hepatol 2007;46:12–18.
[10] Wang J, Leclercq I, Brymora JM, Xu N, Ramezani-Moghadam M, London RM,
et al. Kupffer cells mediate leptin-induced liver ﬁbrosis. Gastroenterology
2009;137:713–723.
[11] Ding X, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA. The roles of leptin
and adiponectin: a novel paradigm in adipocytokine regulation of liver
ﬁbrosis and stellate cell biology. Am J Pathol 2005;166:1655–1669.
[12] Barazzoni R, Bosutti A, Stebel M, Cattin MR, Roder E, Visintin L, et al. Ghrelin
regulates mitochondrial–lipid metabolism gene expression and tissue fat
distribution in liver and skeletal muscle. Am J Physiol Endocrinol Metab
2005;288:E228–E235.
[13] Caligiuri A, Bertolani C, Guerra CT, Alefﬁ S, Galastri S, Trappoliere M, et al.
Adenosine monophosphate-activated protein kinase modulates the acti-
vated phenotype of hepatic stellate cells. Hepatology 2008;47:668–676.
[14] Bataller R, Sancho-Bru P, Gines P, Lora JM, Al-Garawi A, Sole M, et al.
Activated human hepatic stellate cells express the renin-angiotensin system
and synthesize angiotensin II. Gastroenterology 2003;125:117–125.
[15] Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin
resistance. Annu Rev Physiol 2008;70:537–556.
[16] Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents.
Nature 2000;407:908–913.
[17] Wortley KE, del Rincon JP, Murray JD, Garcia K, Iida K, Thorner MO, et al.
Absence of ghrelin protects against early-onset obesity. J Clin Invest
2005;115:3573–3578.
[18] Lanthier N, Horsmans Y, Leclercq IA. The metabolic syndrome: how it may
inﬂuence hepatic stellate cell activation and hepatic ﬁbrosis. Curr Opin Clin
Nutr Metab Care 2009;12:404–411.
[19] Murata M, Okimura Y, Iida K, Matsumoto M, Sowa H, Kaji H, et al. Ghrelin
modulates the downstream molecules of insulin signaling in hepatoma cells.
J Biol Chem 2002;277:5667–5674.1 vol. 55 j 221–223 223
